XML 135 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1
Net Loss per Share (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Earnings per share:    
Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss

 

   2024   2023 
  

Nine Months Ended

September 30,

 
   2024   2023 
Options to purchase Common Stock   147,000    913,856 
Unvested restricted stock units and awards   1,371,950    177,275 
Warrants for Common Stock   12,314,114    3,112,165 
Series A-1 preferred stock   -    2,839,957 
Series A-2 preferred stock   -    3,415,923 
Convertible promissory notes   1,118,735    4,643,325 
Total   14,951,799    15,102,501 

   2023   2022 (1) 
   For the year ended December 31, 
   2023   2022 (1) 
Employee stock options   -    913,856 
Restricted stock awards   -    177,276 
Warrants for common stock   12,181,019    2,367,607 
Series A-1 preferred stock   -    2,839,957 
Series A-2 preferred stock   -    3,415,923 
Convertible promissory notes   -    3,786,610 
Total common stock equivalents   12,181,019    13,501,229 

 

(1)Retroactively restated for the reverse recapitalization in Note 3.